Research programme: diagnostic and therapeutic agents- Indi Molecular

Drug Profile

Research programme: diagnostic and therapeutic agents- Indi Molecular

Alternative Names: Akt PCC; Akt specific branched peptide triligand - Caltech/Integrated Diagnostics; Protein catalysed capture agents - Indi Molecular

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator California Institute of Technology/CalTech; Integrated Diagnostics
  • Class Diagnostic agents; Imaging agents; Peptides
  • Mechanism of Action Positron-emission tomography enhancers; Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer(Diagnosis) in USA
  • 29 May 2014 Indi Molecular and Sigma Aldrich enters into a co-development agreement to explore the use of protein catalysed capture agents to specifically interact with proteins
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top